GigaMune
GigaMune develops diverse viral pseudotypes for repeat-dose in vivo CAR-T delivery and shows anti-CD19 mouse proof of concept. Proposed sequential dosing and immune evasion are platform hypotheses; human redosing safety and efficacy have not been established.
Corporate information
- Company entity
- GigaMune
- Headquarters / principal office
- San Francisco, California, United States ↗
- Founded
- 2017 ↗
- Ownership / capital status
- PrivateNot verified ↗
- Official corporate reference
- https://www.gigamune.com/?p=3774 ↗
- LinkedIn company page
- LinkedIn ↗ ↗
Profile review: 2026-11-04 · Fields retain their individual source dates. Undisclosed values are not zero; early or historical events do not establish the latest financing. Awards and acquisitions are distinguished from equity rounds.
Start with public sources and capability boundaries; company claims are not independent certification.
Ask AI ↗Public evidence snapshot
GigaMune develops diverse viral pseudotypes for repeat-dose in vivo CAR-T delivery and shows anti-CD19 mouse proof of concept. Proposed sequential dosing and immune evasion are platform hypotheses; human redosing safety and efficacy have not been established.
This profile is a research snapshot, not a company endorsement. Check original sources for current information.
Original sources
- GigaMune — multiple-dose in vivo CAR-T — official page checked
- Matching company-operated LinkedIn page / official domain